ARTICLE | Clinical News
Inspiolto Respimat: Additional Phase III data
February 15, 2016 8:00 AM UTC
Additional data from the double-blind, crossover, international Phase III ENERGITO trial in about 229 patients with moderate to severe COPD showed that once-daily oral Stiolto Respimat improved FEV1 A...